CEO Recombinant Antibody Technology
Marianne Brüggemann obtained her PhD in Natural Sciences from the University of Cologne, Germany, working on antibody diversification in Prof. K. Rajewsky’s laboratory. Her postdoctoral work at the University of Cambridge in Prof. H. Waldmann’s laboratory identified the layout of the rat immunoglobulin heavy-chain (IgH) locus, which provided an important contribution to early engineering of ‘humanized’ rodent antibodies. At that time the need for fully human therapeutic antibodies was realized and she assembled a germline configured human IgH construct, which, in collaboration with M. Neuberger, MRC, and A. Surani, Babraham, generated the first transgenic mice expressing human antibody repertoires. Patented work continued on human antibody expression, knockout technology, artificial chromosomes and transgenic animals expressing single-chain antibody repertoires. Her academic research at the Babraham Institute was followed in 2010 by becoming Research Director of RAT, where she established transgenic opportunities including domain antibody repertoires; the smallest antigen-binders.